Marc A. Becker is CFO at CONCERT PHARMACEUTICALS, INC. (CNCE). They have made 1 open-market trade across 1 company since 2020, most recently 2023-03-06.
CIK 0001618060
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CNCE | 123,863 | $1.0M |
Shares reported on the most recent Form 4, priced at the 2023-02-16 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CNCE | SELL · 10b5-1 | 2023-02-15 | 2023-02-16 | $8.33 | $31K | +0.1% | N/A | N/A |
| CNCE | SELL | 2023-01-30 | 2023-01-31 | $8.35 | $142K | -0.2% | +0.1% | N/A |
| CNCE | SELL · 10b5-1 | 2023-01-06 | 2023-01-09 | $7.25 | $21K | +14.0% | +15.0% | N/A |
| CNCE | SELL · 10b5-1 | 2022-02-14 | 2022-02-16 | $3.08 | $12K | -10.9% | +5.3% | +29.9% |
| CNCE | SELL · 10b5-1 | 2022-01-05 | 2022-01-07 | $3.20 | $9K | -0.6% | +3.2% | +14.3% |
| CNCE | SELL · 10b5-1 | 2021-08-16 | 2021-08-17 | $3.28 | $24K | +12.4% | +2.7% | +21.5% |
| CNCE | SELL · 10b5-1 | 2021-02-16 | 2021-02-17 | $7.32 | $28K | -4.7% | -14.8% | -44.3% |
| CNCE | SELL · 10b5-1 | 2020-08-17 | 2020-08-19 | $10.24 | $29K | -3.9% | +6.5% | +10.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.